Bone Biologics (OTC:BBLG) Stock Price Up 1.9% – Should You Buy?

Bone Biologics Co. (OTC:BBLGGet Free Report)’s share price traded up 1.9% on Thursday . The stock traded as high as $0.87 and last traded at $0.86. 296,298 shares were traded during trading, an increase of 60% from the average session volume of 185,384 shares. The stock had previously closed at $0.84.

Bone Biologics Stock Down 16.3 %

The stock has a market capitalization of $2.36 million, a PE ratio of -0.01 and a beta of 0.53. The firm has a 50 day moving average price of $0.94 and a 200-day moving average price of $1.22.

Bone Biologics Company Profile

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.

Featured Stories

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.